FDA Approval Alert: The Need-to-Know | TXL007-CDx in Prostate Cancer

In March 2025, the FDA approved TXL007-CDx, a kit for the preparation of gallium-68 gozetotide (68Ga) injection for patients with prostate cancer.

FDA Approves PET Imaging Agent for Prostate Cancer
FDA Approves PET Imaging Agent for Prostate Cancer
Article
Mar 21, 2025 1:27 PM
The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.